admin

The Expanding Role of APIs Amid Rising Global Health Issues

Escalating Health Issues and API The Active Pharmaceutical Ingredients (API) market is increasing constantly, as it is a crucial active raw material used in medicines to determine their strength, dosage and effectiveness, which is important in the treatment of chronic diseases, including cardiovascular disorders, diabetes, and cancer. And the stats regarding the rise in these types […]

The Expanding Role of APIs Amid Rising Global Health Issues Read More »

Global Expansion of API Manufacturing to Reduce Dependence on India and China

India and China are dominating the API industry globally, driven by several factors, including low labour costs, a highly skilled workforce, strong infrastructure, numerous USFDA/EMA-approved plants, and government-friendly policies. For instance, India’s investment commitment (i.e., ₹3,938.5 crore) has exceeded this figure and reached ₹4,570 crore in 2025, specifically in this sector. These numbers not only

Global Expansion of API Manufacturing to Reduce Dependence on India and China Read More »

Rising Depression and Anxiety Cases Propel Desvenlafaxine Succinate Market: Growing at a 2.8 CAGR

Desvenlafaxine succinate market strengthens as FDA approvals support broader antidepressant therapy adoption. Industry Overview Desvenlafaxine succinate market is growing at a CAGR of 2.8% during the forecast period (2025-2035). Desvenlafaxine Succinate is a serotonin-norepinephrine reuptake inhibitor (SNRI), given mostly for the treatment of major depressive disorder (MDD) and occasionally for anxiety-related ailments. Sold under brand

Rising Depression and Anxiety Cases Propel Desvenlafaxine Succinate Market: Growing at a 2.8 CAGR Read More »

Dr. Reddy’s Receives US FDA Approval for Middleburgh API Facility: A Major Compliance and Milestone

Dr. Reddy’s Laboratories has officially received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (US FDA) for the Active Pharmaceutical Ingredient (API) manufacturing facility in Middleburgh, New York. The report has been issued after a Good Manufacturing Practice (GMP) inspection, which has been categorized as Voluntary Action Indicated (VAI), and the

Dr. Reddy’s Receives US FDA Approval for Middleburgh API Facility: A Major Compliance and Milestone Read More »

Battling Infections Globally: Amoxicillin Sodium Market Set to Grow at 1.9% CAGR

Increasing infectious disease prevalence, growth of generic formulations, and growing healthcare availability are fueling the Amoxicillin Sodium market. Industry Overview Amoxicillin sodium market is growing at a CAGR of 1.9% during the forecast period (2025-2035). This expansion is driven by growing bacterial infections, broader access to healthcare globally, and the prevalent trend towards affordable generic

Battling Infections Globally: Amoxicillin Sodium Market Set to Grow at 1.9% CAGR Read More »

Zydus Lifesciences Received All-Clear from the US FDA for Gujarat API Plant

Zydus Lifesciences has reached a significant regulatory milestone as the US Food and Drug Administration (FDA) has given a No Action Indicated (NAI) status to its Active Pharmaceutical Ingredient (API) manufacturing plant in Ankleshwar, Gujarat, highlighting the company’s dedication to manufacturing excellence and quality assurance globally. US FDA Surveillance Inspection & Outcome From March 10

Zydus Lifesciences Received All-Clear from the US FDA for Gujarat API Plant Read More »

Tamsulosin Hydrochloride Market Expands on Rising BPH Cases: Estimated to Grow at a 6.3% CAGR Through 2035

Tamsulosin Hydrochloride Market finds new growth paths through off-label prescribing for female urinary retention and chronic pelvic pain. Industry Overview Tamsulosin hydrochloride market is growing at a CAGR of 6.3% during the forecast period (2025-2035). The Tamsulosin Hydrochloride Market is witnessing substantial growth following the increasing incidence of Benign Prostatic Hyperplasia (BPH), the growing geriatric

Tamsulosin Hydrochloride Market Expands on Rising BPH Cases: Estimated to Grow at a 6.3% CAGR Through 2035 Read More »

Oxcarbazepine Market is Growing at a CAGR of 4.2% During 2025–2035

Oxcarbazepine market is gaining momentum amid increasing epilepsy prevalence, generic drug approvals, and growing neurological disorder diagnoses globally. Industry Overview Oxcarbazepine market was valued at a CAGR of 4.2% during the forecast period (2025-2035). Oxcarbazepine, a carbamazepine structural derivative, is mainly applied in treating epilepsy and seizures. Its enhanced safety profile and fewer drug interactions

Oxcarbazepine Market is Growing at a CAGR of 4.2% During 2025–2035 Read More »

Rise in Cardiovascular Emergencies Powers Nicardipine Hydrochloride Market Growth: Valued at $452 Million in 2024

The rising burden of cardiovascular disease is turning the spotlight on intravenous vasodilators, propelling the Nicardipine Hydrochloride Market forward. Industry Overview Nicardipine hydrochloride market Nicardipine Hydrochloride is a calcium channel blocker mainly used in the treatment of angina and high blood pressure, and its need is rising internationally owing to the growing incidence of cardiovascular

Rise in Cardiovascular Emergencies Powers Nicardipine Hydrochloride Market Growth: Valued at $452 Million in 2024 Read More »

Increasing IBD Cases Propel Mesalamine Market: Valued at $1.8 Billion in 2024, Forecast to Reach $3.4 Billion by 2035 at 6.8% CAGR

The Mesalamine Market is no longer just about treatment it’s about access, affordability, and global reach, led by a new wave of generic approvals. Industry Overview Mesalamine Mesalamine known as 5-aminosalicylic acid or 5-ASA is a medication used to treat Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis. Mesalamine is a class of

Increasing IBD Cases Propel Mesalamine Market: Valued at $1.8 Billion in 2024, Forecast to Reach $3.4 Billion by 2035 at 6.8% CAGR Read More »